mir-145
(Redirected from MIR145 (gene))
| MIR145 | |||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Identifiers | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Aliases | MIR145, microRNA 145, MIRN145, miR-145, miRNA145, MIRN145 microRNA, human | ||||||||||||||||||||||||||||||||||||||||||||||||||
| External IDs | OMIM: 611795; GeneCards: MIR145; OMA:MIR145 - orthologs | ||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| Wikidata | |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| mir-145 | |
|---|---|
 Conserved secondary structure of mir-145 | |
| Identifiers | |
| Symbol | mir-145 |
| Rfam | RF00675 |
| miRBase family | MIPF0000079 |
| Other data | |
| RNA type | microRNA |
| Domain(s) | Eukaryota; |
| PDB structures | PDBe |
In molecular biology, mir-145 microRNA is a short RNA molecule that in humans is encoded by the MIR145 gene. MicroRNAs function to regulate the expression levels of other genes by several mechanisms.[3]
Targets
[edit]MicroRNAs are involved in down-regulation of a variety of target genes. Götte et al. have shown that experimental over-expression of mir-145 down-regulates the junctional cell adhesion molecule JAM-A as well as the actin bundling protein fascin in breast cancer and endometriosis cells, resulting in a reduction of cell motility.[4][5] Larsson et al.[6] showed that miR-145 targets the 3' UTR of the FLI1 gene, a finding that was later supported by Zhang et al.[7]
Role in cancer
[edit]miR-145 is hypothesised to be a tumor suppressor.[8] miR-145 has been shown to be down-regulated in breast cancer.[5] miR-145 is also involved in colon cancer [7][9][10] and acute myeloid leukemia.[11]
References
[edit]- ^ a b c GRCh38: Ensembl release 89: ENSG00000276365 – Ensembl, May 2017
- ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ "Entrez Gene: MicroRNA 145". Retrieved 2015-01-26.
- ^ Adammek M (2013). "MicroRNA miR-145 inhibits proliferation, invasiveness, and stem cell phenotype of an in vitro endometriosis model by targeting multiple cytoskeletal elements and pluripotency factors". Fertility and Sterility. 99 (5): 1346–1355.e5. doi:10.1016/j.fertnstert.2012.11.055. PMID 23312222.
- ^ a b Götte M, Mohr C, Koo CY, et al. (Dec 2010). "miR-145-dependent targeting of junctional adhesion molecule A and modulation of fascin expression are associated with reduced breast cancer cell motility and invasiveness". Oncogene. 29 (50): 6569–80. doi:10.1038/onc.2010.386. PMID 20818426. S2CID 11455884.
- ^ Larsson E, Fredlund Fuchs P, Heldin J, et al. (2009). "Discovery of microvascular miRNAs using public gene expression data: miR-145 is expressed in pericytes and is a regulator of Fli1". Genome Medicine. 1 (11): 108. doi:10.1186/gm108. PMC 2808743. PMID 19917099.
- ^ a b Zhang J, Guo H, Zhang H, et al. (Jan 2011). "Putative tumor suppressor miR-145 inhibits colon cancer cell growth by targeting oncogene Friend leukemia virus integration 1 gene". Cancer. 117 (1): 86–95. doi:10.1002/cncr.25522. PMC 2995010. PMID 20737575.
- ^ Sachdeva M, Zhu S, Wu F, et al. (Mar 2009). "p53 represses c-Myc through induction of the tumor suppressor miR-145". Proceedings of the National Academy of Sciences of the United States of America. 106 (9): 3207–12. Bibcode:2009PNAS..106.3207S. doi:10.1073/pnas.0808042106. PMC 2651330. PMID 19202062.
- ^ Slaby O, Svoboda M, Fabian P, et al. (2007). "Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer". Oncology. 72 (5–6): 397–402. doi:10.1159/000113489. PMID 18196926. S2CID 207615720.
- ^ Mazza T, Mazzoccoli G, Fusilli C, et al. (2016-05-19). "Multifaceted enrichment analysis of RNA-RNA crosstalk reveals cooperating micro-societies in human colorectal cancer". Nucleic Acids Research. 44 (9): 4025–4036. doi:10.1093/nar/gkw245. ISSN 1362-4962. PMC 4872111. PMID 27067546.
- ^ Starczynowski DT, Morin R, McPherson A, et al. (Jan 2011). "Genome-wide identification of human microRNAs located in leukemia-associated genomic alterations". Blood. 117 (2): 595–607. doi:10.1182/blood-2010-03-277012. PMID 20962326.
Further reading
[edit]- Zhang J, Guo H, Qian G, et al. (2010). "MiR-145, a new regulator of the DNA fragmentation factor-45 (DFF45)-mediated apoptotic network". Molecular Cancer. 9: 211. doi:10.1186/1476-4598-9-211. PMC 2924312. PMID 20687965.
- Zaman MS, Chen Y, Deng G, et al. (Jul 2010). "The functional significance of microRNA-145 in prostate cancer". British Journal of Cancer. 103 (2): 256–64. doi:10.1038/sj.bjc.6605742. PMC 2906737. PMID 20588276.
- Sachdeva M, Mo YY (2010). "miR-145-mediated suppression of cell growth, invasion and metastasis". American Journal of Translational Research. 2 (2): 170–80. PMC 2855636. PMID 20407606.
- Kano M, Seki N, Kikkawa N, et al. (Dec 2010). "miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma". International Journal of Cancer. 127 (12): 2804–14. doi:10.1002/ijc.25284. PMID 21351259. S2CID 25480039.
- Chiyomaru T, Enokida H, Tatarano S, et al. (Mar 2010). "miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer". British Journal of Cancer. 102 (5): 883–91. doi:10.1038/sj.bjc.6605570. PMC 2833258. PMID 20160723.
- Gregersen LH, Jacobsen AB, Frankel LB, et al. (2010). Kudla G (ed.). "MicroRNA-145 targets YES and STAT1 in colon cancer cells". PLOS ONE. 5 (1): e8836. Bibcode:2010PLoSO...5.8836G. doi:10.1371/journal.pone.0008836. PMC 2809101. PMID 20098684.
- Sachdeva M, Mo YY (Jan 2010). "MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1". Cancer Research. 70 (1): 378–87. doi:10.1158/0008-5472.CAN-09-2021. PMC 2805032. PMID 19996288.
- Larsson E, Fredlund Fuchs P, Heldin J, et al. (2009). "Discovery of microvascular miRNAs using public gene expression data: miR-145 is expressed in pericytes and is a regulator of Fli1". Genome Medicine. 1 (11): 108. doi:10.1186/gm108. PMC 2808743. PMID 19917099.
- Ostenfeld MS, Bramsen JB, Lamy P, et al. (Feb 2010). "miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors". Oncogene. 29 (7): 1073–84. doi:10.1038/onc.2009.395. PMID 19915607. S2CID 25309570.
- Starczynowski DT, Kuchenbauer F, Argiropoulos B, et al. (Jan 2010). "Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype". Nature Medicine. 16 (1): 49–58. doi:10.1038/nm.2054. PMID 19898489. S2CID 7987486.
- Arndt GM, Dossey L, Cullen LM, et al. (2009). "Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer". BMC Cancer. 9: 374. doi:10.1186/1471-2407-9-374. PMC 2770572. PMID 19843336.
- Zhang C (Nov 2009). "MicroRNA-145 in vascular smooth muscle cell biology: a new therapeutic target for vascular disease". Cell Cycle. 8 (21): 3469–73. doi:10.4161/cc.8.21.9837. PMC 3593963. PMID 19829088.
- Zeng L, Carter AD, Childs SJ (Oct 2009). "miR-145 directs intestinal maturation in zebrafish". Proceedings of the National Academy of Sciences of the United States of America. 106 (42): 17793–8. Bibcode:2009PNAS..10617793Z. doi:10.1073/pnas.0903693106. PMC 2764920. PMID 19805048.
- Spizzo R, Nicoloso MS, Lupini L, et al. (Feb 2010). "miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells". Cell Death and Differentiation. 17 (2): 246–54. doi:10.1038/cdd.2009.117. PMC 3648637. PMID 19730444.
- Xin M, Small EM, Sutherland LB, et al. (Sep 2009). "MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury". Genes & Development. 23 (18): 2166–78. doi:10.1101/gad.1842409. PMC 2751981. PMID 19720868.
- Cordes KR, Sheehy NT, White MP, et al. (Aug 2009). "miR-145 and miR-143 regulate smooth muscle cell fate and plasticity". Nature. 460 (7256): 705–10. Bibcode:2009Natur.460..705C. doi:10.1038/nature08195. PMC 2769203. PMID 19578358.
- Cheng Y, Liu X, Yang J, et al. (Jul 2009). "MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation". Circulation Research. 105 (2): 158–66. doi:10.1161/CIRCRESAHA.109.197517. PMC 2728297. PMID 19542014.
- Cho WC, Chow AS, Au JS (Aug 2009). "Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation". European Journal of Cancer. 45 (12): 2197–206. doi:10.1016/j.ejca.2009.04.039. PMID 19493678.
- Chivukula RR, Mendell JT (May 2009). "Abate and switch: miR-145 in stem cell differentiation". Cell. 137 (4): 606–8. doi:10.1016/j.cell.2009.04.059. PMID 19450510.
- Xu N, Papagiannakopoulos T, Pan G, et al. (May 2009). "MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells". Cell. 137 (4): 647–58. doi:10.1016/j.cell.2009.02.038. PMID 19409607. S2CID 18601406.
- La Rocca G, Badin M, Shi B, et al. (Aug 2009). "Mechanism of growth inhibition by MicroRNA 145: the role of the IGF-I receptor signaling pathway". Journal of Cellular Physiology. 220 (2): 485–91. doi:10.1002/jcp.21796. PMID 19391107. S2CID 44343336.
- Wang S, Bian C, Yang Z, et al. (May 2009). "miR-145 inhibits breast cancer cell growth through RTKN". International Journal of Oncology. 34 (5): 1461–6. doi:10.3892/ijo_00000275. PMID 19360360.
- Zheng L, Pu J, Qi T, et al. (Feb 2013). "miRNA-145 targets v-ets erythroblastosis virus E26 oncogene homolog 1 to suppress the invasion, metastasis, and angiogenesis of gastric cancer cells". Molecular Cancer Research. 11 (2): 182–93. doi:10.1158/1541-7786.MCR-12-0534. PMID 23233482.